Wells Fargo & Company Issues Pessimistic Forecast for Fate Therapeutics (NASDAQ:FATE) Stock Price
Fate Therapeutics (NASDAQ:FATE – Free Report) had its target price trimmed by Wells Fargo & Company from $5.00 to $4.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock. Several other brokerages have also recently weighed in on FATE. Needham & Company […]
Fate Therapeutics (NASDAQ:FATE – Free Report) had its target price trimmed by Wells Fargo & Company from $5.00 to $4.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock. Several other brokerages have also recently weighed in on FATE. Needham & Company […]
